Search
ANI Pharmaceuticals Inc
ANIPAdd to Watchlist
83.050USD
+0.270+0.33%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.89BMarket Cap
20.19P/E TTM
More Details of ANI Pharmaceuticals Inc Company
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals Inc Info
Ticker SymbolANIP
Company nameANI Pharmaceuticals Inc
IPO dateMay 04, 2000
CEOLalwani (Nikhil Suresh)
Number of employees897
Security typeOrdinary Share
Fiscal year-endMay 04
Address210 Main Street West
CityBAUDETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code56623
Phone12186343500
Websitehttps://www.anipharmaceuticals.com/
Ticker SymbolANIP
IPO dateMay 04, 2000
CEOLalwani (Nikhil Suresh)
Company Executives of ANI Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
FAQs
Who are the top five shareholders of ANI Pharmaceuticals Inc?
The top five shareholders of ANI Pharmaceuticals Inc are: Mr. Chad Gassert
How many institutions hold shares of ANI Pharmaceuticals Inc (ANIP)?
As of 2026Q1, 555 institutions hold shares of ANI Pharmaceuticals Inc, with a combined market value of approximately 23.15M, accounting for 101.74% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 57726.00.
What is the biggest source of revenue for ANI Pharmaceuticals Inc?
In 2026Q1, the Sales of generic pharmaceutical products business generated the highest revenue for ANI Pharmaceuticals Inc, amounting to 384.11M and accounting for 43.48% of total revenue.